Catalyst Pharmaceuticals Inc (CPRX) Forecasted to Post Q1 2017 Earnings of ($0.06) Per Share
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Stock analysts at Roth Capital issued their Q1 2017 EPS estimates for Catalyst Pharmaceuticals in a research note issued to investors on Monday. Roth Capital analyst S. Henry forecasts that the firm will post earnings of ($0.06) per share for the quarter. Roth Capital also issued estimates for Catalyst Pharmaceuticals’ Q2 2017 earnings at ($0.06) EPS, Q3 2017 earnings at ($0.06) EPS and Q4 2017 earnings at ($0.07) EPS.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, March 15th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02.
Your IP Address:
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/catalyst-pharmaceuticals-inc-cprx-forecasted-to-post-q1-2017-earnings-of-0-06-per-share.html
Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Monday. Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th.
Catalyst Pharmaceuticals (NASDAQ:CPRX) opened at 1.66 on Tuesday. The firm’s market capitalization is $137.56 million. The company’s 50-day moving average price is $1.17 and its 200-day moving average price is $1.14. Catalyst Pharmaceuticals has a 1-year low of $0.51 and a 1-year high of $1.81.
Hedge funds have recently bought and sold shares of the company. Kingdon Capital Management L.L.C. acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at about $794,000. Baker BROS. Advisors LP acquired a new stake in Catalyst Pharmaceuticals during the third quarter valued at about $5,561,000. Berson & Corrado Investment Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 76.1% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 181,900 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 78,600 shares during the last quarter. Finally, Royal Bank of Canada acquired a new stake in Catalyst Pharmaceuticals during the second quarter valued at about $117,000. 28.13% of the stock is currently owned by institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.